Toggle Main Menu Toggle Search

Open Access padlockePrints

Long-Term Preservation of Cardiac Structure and Function After Adeno-Associated Virus Serotype 9-Mediated Microdystrophin Gene Transfer in mdx Mice

Lookup NU author(s): Dr Ralf Bauer, Professor Hanns Lochmuller

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Dystrophin plays an important role in muscle contraction, linking the intracellular cytoskeleton to the extracellular matrix. Mutations of the dystrophin gene leading to a complete loss of the protein cause Duchenne muscular dystrophy (DMD), frequently associated with severe cardiomyopathy. Early clinical trials in DMD using gene transfer to skeletal muscle are underway, but gene transfer to dystrophic cardiac muscle has not yet been tested in humans. The aim of this study was to develop an optimized protocol for cardiac gene therapy in the mouse model of dystrophin deficiency (mdx), using a cardiac promoter for expression of a microdystrophin (mu Dys) transgene packaged into an adeno-associated virus serotype 9 vector (AAV9). In this study adult mdx mice were intravenously injected with 1 x 10(12) genomic particles of AAV9 vectors carrying a cDNA encoding mu Dys under the control of either a ubiquitously active cytomegalovirus (CMV) promoter or a cardiac-specific CMV-enhanced myosin light chain (MLC0.26) promoter. After 10 months, both AAV9 vectors led to sustained mu Dys expression in cardiac muscle, but the MLC promoter conferred about 4-fold higher protein levels. AAV9-CMV-MLC0.26-mu Dys resulted in significant protection of cardiac morphology and function as assessed by histopathology, echocardiography, and left ventricular catheterization. In conclusion, we established an AAV9-mediated gene transfer approach for efficient and specific long-term mu Dys expression in the hearts of mdx mice, resulting in a sustained therapeutic effect. Thus, this approach might be a basis for further translation into a treatment strategy for DMD-associated cardiomyopathy.


Publication metadata

Author(s): Schinkel S, Bauer R, Bekeredjian R, Stucka R, Rutschow D, Lochmuller H, Kleinschmidt JA, Katus HA, Muller OJ

Publication type: Article

Publication status: Published

Journal: Human Gene Therapy

Year: 2012

Volume: 23

Issue: 6

Pages: 566-575

Print publication date: 09/03/2012

ISSN (print): 1043-0342

ISSN (electronic): 1557-7422

Publisher: Mary Ann Liebert, Inc. Publishers

URL: http://dx.doi.org/10.1089/hum.2011.017

DOI: 10.1089/hum.2011.017


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
German Cancer Research Center (DKFZ)
Benni & Co-Muscle Dystrophy Parent Organization
G0601943Medical Research Council UK through the Centre for Neuromuscular Diseases
MU 1654/3-2Deutsche Forschungsgemeinschaft

Share